Thrivent Financial for Lutherans Sells 28,859 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Thrivent Financial for Lutherans lessened its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 3.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 839,461 shares of the medical equipment provider's stock after selling 28,859 shares during the quarter. Thrivent Financial for Lutherans owned about 0.42% of Zimmer Biomet worth $88,672,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. CKW Financial Group increased its stake in Zimmer Biomet by 11.7% in the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider's stock valued at $101,000 after purchasing an additional 100 shares during the last quarter. FWG Holdings LLC lifted its holdings in Zimmer Biomet by 2.9% in the third quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider's stock valued at $372,000 after acquiring an additional 101 shares during the period. Romano Brothers AND Company boosted its position in shares of Zimmer Biomet by 1.1% in the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider's stock worth $1,000,000 after buying an additional 102 shares in the last quarter. Dorsey & Whitney Trust CO LLC boosted its position in shares of Zimmer Biomet by 2.3% in the 4th quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider's stock worth $485,000 after buying an additional 102 shares in the last quarter. Finally, M&T Bank Corp boosted its position in shares of Zimmer Biomet by 0.4% in the 4th quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider's stock worth $2,834,000 after buying an additional 108 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Remove Ads

Insider Buying and Selling at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares of the company's stock, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.95% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ZBH shares. Royal Bank of Canada dropped their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, February 7th. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. JMP Securities reissued a "market outperform" rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Raymond James lowered their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. upgraded Zimmer Biomet from a "neutral" rating to an "overweight" rating and increased their target price for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $124.15.

Zimmer Biomet Price Performance

Zimmer Biomet stock traded down $0.99 on Friday, reaching $110.79. The company's stock had a trading volume of 2,942,594 shares, compared to its average volume of 1,498,375. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. The company has a market cap of $22.05 billion, a price-to-earnings ratio of 24.90, a PEG ratio of 1.95 and a beta of 1.04. The business's fifty day moving average price is $106.74 and its 200 day moving average price is $106.86. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the company earned $2.20 earnings per share. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.87%. Zimmer Biomet's dividend payout ratio is 21.57%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.